Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24535944 | 0.89 | KCNH2 (0.38) | SAT1KCNH2 | |
| SCHEMBL19083192 | 0.86 | GNAI3 (0.37) | SAT1LMNASMN1; SMN2HTTHRH3 | |
| SCHEMBL19768945 | 0.84 | SAT1 (0.36) | SAT1 | |
| SCHEMBL19083173 | 0.84 | ADRB3 (0.37) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL19083185 | 0.83 | GNAI3 (0.44) | SAT1LMNASMN1; SMN2HTTADRB3 | |
| SCHEMBL19098716 | 0.82 | LMNA (0.33) | SAT1LMNASMN1; SMN2HTTHRH3 | |
| SCHEMBL1484874 | 0.81 | LMNA (0.36) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL552030 | 0.81 | LMNA (0.36) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL19083202 | 0.81 | ADRB3 (0.36) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL21725304 | 0.81 | ADRB3 (0.36) | LMNASMN1; SMN2HTTHRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239629-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 | Plexium, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | SAT1 4760/4885LMNA 4393/4885SMN1; SMN2 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.